cytarabine • etoposide IV • daunorubicin • mitoxantrone • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • thioguanine • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)

5ms

AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P3, N=218, Completed, Children's Oncology Group | Active, not recruiting --> Completed

5 months ago

Trial completion

cytarabine • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)

9ms

AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov)

P3, N=1895, Active, not recruiting, National Cancer Institute (NCI)

9 months ago

Trial completion date

CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule) • MPO (Myeloperoxidase)

CD22 expression

cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexamethasone injection

9ms

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)

P3, N=1400, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting

9 months ago

Enrollment closed

FLT3 (Fms-related tyrosine kinase 3)

Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • dexrazoxane

over1year

AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P3, N=218, Active, not recruiting, Children's Oncology Group | Trial completion date: Jul 2023 --> Jun 2024

over 1 year ago

Trial completion date

FLT3 (Fms-related tyrosine kinase 3)

over1year

AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P3, N=669, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Apr 2024

over 1 year ago

Trial completion date

cytarabine • cyclophosphamide • etoposide IV • Blincyto (blinatumomab) • methotrexate • vincristine • mitoxantrone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)

3years

ANTIMETABOLIC COOPERATIVITY WITH THE CLINICALLY-APPROVED L-ASPARAGINASE AND TYROSINE KINASE INHIBITORS TO ERADICATE CML STEM CELLS. (PubMed, Mol Metab)

We investigated metabolic pathways responsible for CML surviving Imatinib exposure and its potential therapeutic utility to improve the efficiency of TKI against CML stem cells. The combination of TKI with L-asparaginase reactivated the intinsic apoptotic pathway leading to efficient CML cell death. Thus, targeting glutamine metabolism with the clinically-approved drug Kidrolase, in combination with TKI which suppresses glycolysis, represents an effective and widely applicable therapeutic strategy for eradicating CML stem cells.

3 years ago

Clinical • Journal

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD34 (CD34 molecule)

imatinib • Kidrolase (L-asparaginase)

4years

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P3, N=1070, Completed, Children's Oncology Group | Trial completion date: Aug 2013 --> Sep 2020

4 years ago

Clinical • Trial completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)

cytarabine • etoposide IV • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase)

4years

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov)

P3, N=256, Recruiting, Children's Oncology Group | Trial primary completion date: Mar 2023 --> Jun 2023

4 years ago

Clinical • Trial primary completion date

GATA1 (GATA Binding Protein 1)

cytarabine • etoposide IV • daunorubicin • mitoxantrone • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Spectrila (asparaginase Escherichia coli)

4years

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)

P3, N=1400, Recruiting, Children's Oncology Group | Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027

4 years ago

Clinical • Trial completion date • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3)

Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Erwinase (erwinia asparaginase) • Kidrolase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • dexrazoxane

over4years

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)

P3, N=1400, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting

over 4 years ago

Clinical • Enrollment open

FLT3 (Fms-related tyrosine kinase 3)

over4years

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P3, N=218, Active, not recruiting, Children's Oncology Group | Completed --> Active, not recruiting

over 4 years ago

Clinical • Enrollment closed

FLT3 (Fms-related tyrosine kinase 3)

cytarabine • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • lestaurtinib (CEP-701) • mercaptopurine • Kidrolase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • cyclophosphamide intravenous

almost5years

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)

P3, N=1400, Not yet recruiting, Children's Oncology Group

almost 5 years ago

Clinical • New P3 trial

FLT3 (Fms-related tyrosine kinase 3)

almost5years

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P3, N=1641, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | Trial completion date: Mar 2019 --> Sep 2027

almost 5 years ago

Clinical • Enrollment closed • Trial completion date

FLT3 (Fms-related tyrosine kinase 3)

FLT3-ITD mutation

sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Spectrila (asparaginase Escherichia coli)